1Q EARNINGS: Enbrel slips, but Amgen maintains guidance
This article was originally published in Scrip
Executive Summary
Amgen's first quarter net sales increased 5% to $4.4bn in the first quarter versus the same period a year ago, but drug sales in the January-to-March period fell 9% compared with the fourth quarter of 2013 due to a drop in Enbrel (etanercept) sales.